Skystar to File Financial Results for First Quarter of 2013 on Wednesday, May
Conference Call to Follow on Thursday, May 16, 2013 at 7:45 AM (EST)
XI'AN, CHINA -- (Marketwired) -- 05/14/13 -- Skystar
Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the
"Company"), a China-based manufacturer and distributor of veterinary
medicines, vaccines, micro-organisms and feed additives, will file
its financial results for the first quarter of the fiscal year 2013
on Wednesday May 15, 2013 at the end of the business day.
Conference Call Information
The Company will host a conference call
on Thursday, May 16, 2013 to discuss its first quarter financial
results. Skystar's conference call will begin promptly at 7:45 a.m.
EST. Mr. Weibing Lu, Skystar's Chairman and Chief Executive Officer,
will host the call, which will be webcast live.
webcast will be made available on the investor relations section of
the Skystar corporate website at
Telephone access to the conference call will be
available in North America by dialing +1 (877) 407-8031 or
internationally by dialing +1 (201) 689-8031.
An audio replay of the conference call will be available
approximately two hours following the conclusion of the call and for
the following 30 day period. To access the replay in North America,
dial +1 (877) 660-6853 or, when calling internationally, dial +1
(201) 612-7415, referencing conference ID # 414186.
To be added to the Company's email distribution for future news
releases, please send your request to firstname.lastname@example.org.
About Skystar Bio-Pharmaceutical Company
Skystar is a China-based
developer and distributor of veterinary healthcare and medical care
products. Skystar has four product lines (veterinary medicines,
micro-organisms, vaccines and feed additives) and over 284 products.
Skystar has formed strategic sales distribution networks covering 29
provinces throughout China. For additional information, please visit
Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995: Certain of the statements made
press release constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These statements can be identified by the use of forward-looking
terminology such as "believe," "expect," "may," "will," "should,"
"project," "plan," "seek," "intend," or "anticipate" or the negative
thereof or comparable terminology. Such statements typically involve
risks and uncertainties and may include financial projections or
information regarding the progress of new product development. Actual
results could differ materially from the expectations reflected in
such forward-looking statements as a result of a variety of factors,
including the risks associated with the effect of changing economic
conditions in The People's Republic of China, variations in cash
flow, reliance on collaborative retail partners and on new product
development, variations in new product development, risks associated
with rapid technological change, and the potential of introduced or
undetected flaws and defects in products, and other risk factors
detailed in reports filed with the Securities and Exchange Commission
from time to time.
Skystar Bio-Pharmaceutical Company
Director and U.S. Representative
Press spacebar to pause and continue. Press esc to stop.